2Villarrubia VG, Caivo C, Romero M, et al. Therapeutic impact of AM3(biological response modifier) on prevention of recurrent acute infections of respiratory tract:analysis of 683 persons at high risk[J]. Acta Toxicol Ther, 1993,14:121-134.
3Emmerich B, Emslander HP, Pachmann K, et al. Local immunity in patients with chronic bronchitis and effects of a bacterial extract,Broncho-Vaxom, on T lymphocytes, macrophages, T-interferon and secretory immunoglobulin A in bronchoalveolar larvage fluid a
4Collet JP, Shapiro P, Erust P, et al. Effects of an immunostimulating agent on acute exacerbations and hospitalization in patients with chronic obstructive pulmonary disease. The PARI-IS study steering committee and research group. Prevention of acute res
5Prieto A, Reyes E, Bernstein ED, et al. Defective natural killer and phagocytic activities in chronic obstructive pulmonary disease are restored by glycophosphopeptical (immunoferon) [J ]. Am J Respir Crit Care Med, 2001,163:1578-1583.
6Janeway CA. Travers P, Hunt S, et al. Host defense against infection. In:Immunology:The immune system in health and disease [M]. 3rd London:Current Biology Publication, 1992.9.1-9.52.
7Bascom R. Differential susceptibility to tobacco smoke: possible mechanisms[J]. Pharmacogenetics , 1991,1:102-106.
8Niedermann MS. The pathogenesis of airway colonization:lessons to be learned from the study of bacterial adherence [J]. Eur Respir J. 1994,7:1737-1740.
9Greenberg SB. Allen M. Wilson J. et al. Respiratory viral infections in adults with and without chronic obstructive disease [J]. Am J Respir Crit Care Med, 2000,162:167-173.
10Sethi S.Bacterial infection and the pathogenesis of COPD Chest [J].2000,117(5 Suppl 1):286-291.
